The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Host genetic factors influence disease progression in chronic hepatitis C
Open accessAbstract
Progressive hepatic fibrosis and cirrhosis develops in 20% to 30% of patients with chronic hepatitis C virus (HCV). We propose that host genetic factors influencing fibrogenesis may account for some of the variability in progression of this disease. In progressive fibrosis of other organs, particularly heart and kidney, production of the profibrogenic cytokine, transforming growth factor β1 (TGF-β1), may be enhanced by angiotensin II, the principal effector molecule of the renin-angiotensin system. The inheritance of polymorphisms in TGF-β1, interleukin 10 (IL-10), tumor necrosis factor α (TNF-α), and genes of the renin-angiotensin system was examined in 128 patients with chronic HCV. The influence of genotypes on the stage of hepatic fibrosis was tested after adjustment for potential confounders (age, gender, alcohol consumption, portal inflammation, and steatosis), which may have independent effects on histological severity. The stage of fibrosis was 0 in 30 (23.4%), 1 in 44 (34.4%), 2 in 27 (21.1%), and 3 or 4 in 27 (21.1%). A statistically significant relationship was seen between inheritance of high TGF-β1- and angiotensinogen (AT)-producing genotypes and the development of progressive hepatic fibrosis. This association persisted after correcting for potential confounders. Patients who inherited neither of the profibrogenic genotypes had no or only minimal fibrosis. Knowledge of these polymorphisms may have prognostic significance in patients with chronic HCV and may direct more aggressive therapy towards those patients with an increased risk of disease progression. The documentation of a significant relationship between AT genotype and fibrosis raises the novel suggestion that angiotensin II may be another mediator of extracellular matrix production in the liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
No adjustments are needed for multiple comparisons.
Rothman, K. J. (1990) · Epidemiology · doi:10.1097/00001648-199001000-00010 · Cited by 5,965
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., & Soubrier, F. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114844 · Cited by 3,767
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
AN INVESTIGATION OF POLYMORPHISM IN THE INTERLEUKIN‐10 GENE PROMOTER
Turner, D. M., Williams, D. M., Sankaran, D., Lazarus, M., Sinnott, P. J., & Hutchinson, I. V. (1997) · European Journal of Immunogenetics · doi:10.1111/j.1365-2370.1997.tb00001.x · Cited by 1,717
Classification of chronic viral hepatitis: a need for reassessment
Scheuer, P. J. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90084-o · Cited by 1,576
Lindpaintner, K., Pfeffer, M. A., Kreutz, R., Stampfer, M. J., Grodstein, F., LaMotte, F., Buring, J., & Hennekens, C. H. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503163321103 · Cited by 899
Wilson, A. G., di Giovine, F. S., Blakemore, A. I. F., & Duff, G. W. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.5.353 · Cited by 881
Fibrosis in Chronic Hepatitis C Correlates Significantly With Body Mass Index and Steatosis
Hourigan, L. F., Macdonald, G. A., Purdie, D., Whitehall, V. H., Shorthouse, C., Clouston, A., & Powell, E. E. (1999) · Hepatology · doi:10.1002/hep.510290401 · Cited by 674
Self-citation
Cited by
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Natural history of chronic hepatitis C
Seeff, L. B. (2002) · Hepatology · doi:10.1053/jhep.2002.36806 · Cited by 1,424
Roles of TGF-beta in hepatic fibrosis
Gressner, A. M. (2002) · Frontiers in Bioscience · doi:10.2741/a812 · Cited by 783
Bataller, R., Schwabe, R. F., Choi, Y. H., Yang, L., Paik, Y. H., Lindquist, J., Qian, T., Schoonhoven, R., Hagedorn, C. H., Lemasters, J. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18212 · Cited by 548
Alberti, A., & Benvegnù, L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00008-4 · Cited by 438
Epidemiology and Natural History of Non-Alcoholic Steatohepatitis
Argo, C. K., & Caldwell, S. H. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.005 · Cited by 389
Reversal of Hepatic Fibrosis — Fact or Fantasy?
Friedman, S. L., & Bansal, M. B. (2006) · Hepatology · doi:10.1002/hep.20974 · Cited by 379
Genetic Polymorphisms and the Progression of Liver Fibrosis: A Critical Appraisal
Bataller, R., North, K. E., & Brenner, D. A. (2003) · Hepatology · doi:10.1053/jhep.2003.50127 · Cited by 355
Noninvasive Measures of Liver Fibrosis
Rockey, D. C., & Bissell, M. D. (2006) · Hepatology · doi:10.1002/hep.21046 · Cited by 349
Transforming growth factor β and the liver
Bissell, M. D., Roulot, D., & George, J. (2001) · Hepatology · doi:10.1053/jhep.2001.28457 · Cited by 348
Hepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
Treatment predictors of a sustained virologic response in hepatitis B and C
Kau, A., Vermehren, J., & Sarrazin, C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.013 · Cited by 324
Induction of innate immune genes in brain create the neurobiology of addiction
Crews, F. T., Zou, J., & Qin, L. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.03.003 · Cited by 313
Liver extracellular matrix in health and disease
Bedossa, P., & Paradis, V. (2003) · The Journal of Pathology · doi:10.1002/path.1397 · Cited by 308
Angiotensin-Converting Enzyme Inhibition Attenuates the Progression of Rat Hepatic Fibrosis
Jonsson, J. R., Clouston, A. D., Ando, Y., Kelemen, L. I., Horn, M. J., Adamson, M. D., Purdie, D. M., & Powell, E. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25480 · Cited by 295
Self-citationConnective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases
Gressner, O. A., & Gressner, A. M. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01826.x · Cited by 270
Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy
Sebastiani, G. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i23.3682 · Cited by 266
Is there a future for TNF promoter polymorphisms?
Bayley, J.-P., Ottenhoff, T. H. M., & Verweij, C. L. (2004) · Genes & Immunity · doi:10.1038/sj.gene.6364055 · Cited by 262
Mesenchymal stem cells in fibrotic diseases—the two sides of the same coin
Qin, L., Liu, N., Bao, C.-L.-M., Yang, D.-Z., Ma, G.-X., Yi, W.-H., Xiao, G.-Z., & Cao, H.-L. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00952-0 · Cited by 114
Hillebrandt, S., Goos, C., Matern, S., & Lammert, F. (2002) · Gastroenterology · doi:10.1053/gast.2002.37069 · Cited by 104
Paladino, N., Flores, A. C., Fainboim, H., Schroder, T., Cuarterolo, M., Lezama, C., Ballerga, E. G., Levi, D., Tanno, H., Costanzo, G., et al. (2010) · Clinical Immunology · doi:10.1016/j.clim.2009.11.004 · Cited by 32
Metadata
- Authors
- Powell, E. E., Edwards-Smith, C. J., Hay, J. L., Clouston, A. D., Crawford, D. H., Shorthouse, C., Purdie, D. M., & Jonsson, J. R.
- Venue
- Hepatology
- Published
- 2000-04
- Volume
- 31
- Issue
- 4
- Pages
- 828-833
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1982964625
- Cited by
- 398
- References
- 34
- FWCI
- 18.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.